argenx SE (ARGX)
ARGXNASDAQ-GSBiotechnology: Biological Products (No Diagnostic Substances)
$963.57
+1.30 (+0.14%) today
Regular session, Nov 10, 2:42 PM ET
- Market cap
- $59.80bn
- P/E
- 33.6
- EPS, last 4 quarters
- $28.66
- Dividend yield
- –
- Day range
- $958.60 to $973.99
- 52-week range
- $661.85 to $1,072.75
- Average volume
- 367.5k
- Previous close
- $962.27
Analysts
19 coveringBuy18 buy, 1 hold, 0 sell
Targets a year out average $1,171.11, +21.5% from here
Earnings
next estimate $7.57Next report
Dec 2025
+28.5%
Mar 2026
+7.0%
Jun 2026
+19.4%
Sep 2026
+4.8%
estimate reported, and the surprise
Financials
No quarterly figures from the source.
News
8 latest- argenx SE Reports Phase 3 ALKIVIA Trial of Efgartigimod Met Primary Endpoint in Autoimmune MyositisFintel · 1 day ago
- iShares Biotechnology ETF Experiences Big OutflowBNK Invest · 1 day ago
- argenx SE Announces Agreement to Acquire Unnatural Products, Inc. for Up to Approximately $1.15 billionFintel · 1 day ago
- 3 Reasons Argenx Could Be a Top Biotech Stock for the Next DecadeThe Motley Fool · 1 day ago
- Argenx To Acquire Unnatural Products In Deal Worth Up To $1.15 Billion RTTNews · 1 day ago
- Halozyme Stock Down Despite Q3 Earnings and Revenue BeatZacks · 4 days ago
- Best Biotech Stocks to Buy Now as AI Stocks Tank: ARGXZacks · 6 days ago
- argenx: 3 Key Takeaways for Long-Term InvestorsThe Motley Fool · Oct 23, 2026
The company
argenx is the immunology innovation company, focused on turning immunology breakthroughs into medicines for patients. The company seeks novel biology wherever it emerges, co-creating with academic researchers through its Immunology Innovation Program (IIP) and investing in promising science, to develop treatments for people living with underserved diseases. By advancing molecules with the potential to reach multiple diseases and patient populations, argenx is building a world-class portfolio. This approach produced the first approved antibody fragment targeting the neonatal Fc receptor (FcRn) and today powers a growing pipeline of early and late-stage programs across several therapeutic areas.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ-GS
- Region
- Europe
- Website
- argenx.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.